Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
(Hepatotoxic substances) |
(→Links) |
||
| (12 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:Fibrates.svg.png|thumb|450px]] | [[File:Fibrates.svg.png|thumb|450px]] | ||
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases | Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. | ||
This fibrate | This fibrate reduces triglyceride and rises HDL-cholesterol<ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_ED007/_pdf How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?]</ref><ref>[https://www.jstage.jst.go.jp/article/jat/22/7/22_27425/_pdf Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.]</ref> | ||
<gallery> | <gallery> | ||
| Line 10: | Line 10: | ||
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | <ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | ||
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar | ursodeoxycholic acid and bezafibrate are under study in the treatment of [[biliar cirrhosis]] (See Figure in gallery). | ||
==Links== | ==Links== | ||
[http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?] | [http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?] | ||
==ATC== | ==[[ATC]]== | ||
Lipid | Lipid modifying agents | ||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
|colspan=2| <center> | |colspan=2| <center> | ||
| Line 20: | Line 20: | ||
<ref>http://www.whocc.no/atc_ddd_index/?code=C10AB02</ref></center> | <ref>http://www.whocc.no/atc_ddd_index/?code=C10AB02</ref></center> | ||
|} | |} | ||
{{refs}} | |||
{{Wikidata|Q577387}} | |||
[[Category:Hepatotoxic substances]] | [[Category:Hepatotoxic substances]] | ||
Latest revision as of 15:21, 25 October 2024
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. This fibrate reduces triglyceride and rises HDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cirrhosis (See Figure in gallery).
Links
Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?
ATC
Lipid modifying agents
